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Abstract: SARS-CoV-2 is the causative agent of COVID-19. Severe COVID-19 disease has been
associated with disseminated intravascular coagulation and thrombosis, but the mechanisms
underlying COVID-19-related coagulopathy remain unknown. The risk of severe COVID-19 disease
is higher in males than in females and increases with age. To identify gene products that may
contribute to COVID-19-related coagulopathy, we analyzed the expression of genes associated
with the Gene Ontology (GO) term “blood coagulation” in the Genotype-Tissue Expression (GTEx)
database and identified four procoagulants, whose expression is higher in males and increases with age
(ADAMTS13, F11, HGFAC, KLKB1), and two anticoagulants, whose expression is higher in females
and decreases with age (C1QTNF1, SERPINA5). However, the expression of none of these genes was
regulated in a proteomics dataset of SARS-CoV-2-infected cells and none of the proteins have been
identified as a binding partner of SARS-CoV-2 proteins. Hence, they may rather generally predispose
individuals to thrombosis without directly contributing to COVID-19-related coagulopathy. In contrast,
the expression of the procoagulant transferrin (not associated to the GO term “blood coagulation”)
was higher in males, increased with age, and was upregulated upon SARS-CoV-2 infection. Hence,
transferrin warrants further examination in ongoing clinic-pathological investigations.
Keywords: SARS-CoV-2; COVID-19; thrombosis; coagulation; coagulopathy; transferrin
1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the
ongoing coronavirus disease 2019 (COVID-19) outbreak [1,2]. SARS-CoV-2 was first detected in
December 2019 in the Chinese city Wuhan and has since spread around the world. The John Hopkins
University Coronavirus Resource Center [3] currently reports more than 16 million confirmed COVID-19
cases and more than 650,000 confirmed COVID-19-related deaths. The majority of SARS-CoV-2
infections are mild with a substantial proportion of asymptomatic cases. However, SARS-CoV-2 causes
in some patients severe life-threatening multi-organ disease [1,4–6].
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Severe COVID-19 disease has been associated with disseminated intravascular coagulation and
thrombosis [1,4–6], but the mechanisms underlying COVID-19-related coagulopathy remain unknown.
It is known, however, that the risk of severe and fatal COVID-19 disease is higher in males than
in females and that it increases with age [7]. Similarly, the risk of coagulation-related pathologies
and thrombosis increases with age and is further enhanced in males [8,9]. Thus, gene products that
(1) are involved in coagulation, (2) change with age, (3) differ in their levels between females and
males, and (4) are regulated in response to SARS-CoV-2 infection represent candidate factors that may
contribute to COVID-19-related coagulopathy and disease severity.
To identify such candidate factors that may be involved in COVID-19-related coagulopathy,
we here performed a combined analysis of a proteomics dataset derived from SARS-CoV-2-infected
cells [10], of a dataset of host cell proteins found to bind to SARS-CoV-2 proteins [11], and of human
gene expression data from the Genotype-Tissue Expression (GTEx) database [12].
2. Materials and Methods
2.1. Data Acquisition
Gene Ontology is an initiative that annotates genes with functions [13]. Genes associated with
the Gene Ontology (GO) term “Blood Coagulation” (GO:0007596) were identified using the online
database AmiGO 2 [13]. This generated a list of 335 unique genes annotated with 23 unique terms
(including “Blood Coagulation” and 22 child terms) for further analysis.
Gene expression data (transcripts per million, TPM) and clinical data for 980 individuals
(17,382 samples from 30 tissues) were downloaded from the GTEx Portal (https://www.gtexportal.org/
home/datasets; GTEx Project, version 8). We also used normalized protein abundance data from a
recent publication [10] in which protein abundance in uninfected and SARS-CoV-2-infected Caco-2
(SARS-CoV-2-susceptible colorectal cancer cell line) cells was quantified. Data were subsequently
normalized using summed intensity normalization for sample loading, followed by internal reference
scaling and Trimmed mean of M normalization.
We also queried the EBI IntAct database (https://www.ebi.ac.uk/intact/) for “annot:dataset
“coronavirus””, and filtered for interactions between human proteins and SARS-CoV-2 proteins.
These SARS-CoV-2-interacting proteins were derived from a study by Gordon et al. [11], in which
29 SARS-CoV-2 proteins were cloned, tagged, and expressed in HEK293T cells, and incubated for 40 h prior
to affinity purification and identification of binding partners by mass spectrometry. This resulted in 332 high
confidence human protein interactors for 26 of the SARS-CoV-2 proteins.
2.2. Data Analysis
Analyses were performed using R3.6.1. Linear models were generated to estimate the relationship
between gene expression and age using the base R function lm, which generated p-values indicating the
significance of the relationship. Models with a p-value <0.05 were considered significant. Plots were
generated using the R package ggplot2. Mean protein abundance (for proteomics data) and median
gene expression TPM (for GTEx data) was plotted using the function ggviolin. p-values indicating the
significance of the difference between gene expression/protein abundance in males and females in each
given age group were the result of a Wilcoxon rank sum test for independent groups. For the proteome
data, we performed a two-sided student’s t-test. Boxplots comparing gene expression in males and
females were generated using the function ggboxplot, for which p-values were the result of a Wilcoxon
rank sum test for independent groups.
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3. Results
3.1. Identification of Genes that May Be Associated with an Increased Coagulation Risk in Males and at an
Older Age
Using AmiGO 2 [12], we identified 335 genes, which are associated with the GO term
“blood coagulation” (GO:0007596). Since the risk of severe COVID-19 disease increases with age and is
higher in males than in females [7], coagulation-associated genes which may be relevant in the context
of COVID-19-related coagulopathy would be expected to differ in their expression between females
and males and change in their expression with age.
An analysis of the genes associated with the GO term “blood coagulation” using the
Genotype-Tissue Expression (GTEx) database [12] resulted in 256 coagulation-associated genes,
that are differently expressed between females and males (Table S1) and 237 genes whose expression
changed with age (Table S2). These lists included many genes, whose products are involved in the
regulation of upstream processes, which may be linked to coagulation in certain cell types and under
certain circumstances but are not core players directly involved in the actual coagulation process.
Examples include members of major signaling cascades such as PI3K or MAPK signaling (Tables S1
and S2). Hence, the functions of these genes were manually annotated to identify candidate genes,
whose products act as procoagulants and anticoagulants (Tables S1 and S2). This resulted in a list of
49 overlapping genes, whose products are directly involved in coagulation (Table S3).
Two groups of genes were considered as candidates, whose products may increase or reduce the
risk of COVID-19-related coagulopathy: (1) procoagulants that display higher expression in males and
increase in their expression with age and (2) anticoagulants that display higher expression in females
and decrease in their expression with age. According to these criteria, we found four procoagulants
(ADAMTS13, F11, HGFAC, KLKB1) and two anticoagulants (C1QTNF1, SERPINA5), whose expression
may predispose males and older individuals to COVID-19-related coagulopathy and severe COVID-19
disease (Table 1, Figure 1, Table S3).
Table 1. Candidate gene products that may be involved in COVID-19-related coagulopathy. Candidates
were either (A) procoagulants (ADAMTS13, F11, HGFAC, KLKB1), which display a lower expression in
females than in males and increase with age, or (B) anticoagulants (C1QTNF1, SERPINA5), which display
higher expression in females than in males and decrease with age.
(A) Procoagulants
Female vs. male Age-associated expression
Relative expression p-value * Direction p-value
ADAMTS13 low 8.9 × 10−8 increase 1.6 × 10−11
F11 low 3.5 × 10−4 increase <2.2 × 10−16
HGFAC low 0.032 increase 0.049
KLKB1 low <2.2 × 10−16 increase 4.3 × 10−6
(B) Anticoagulants
Female vs. male Age-associated expression
Relative expression p-value Direction p-value
C1QTNF1 high 6.7 × 10−13 decrease 2.6 × 10−16
SERPINA5 high 3.7 × 10−3 decrease 2.8 × 10−6
* p-value < 0.05 were considered as significantly different.
3.2. No Overlap between COVID-19-Related Coagulopathy Predisposition Genes and
SARS-CoV-2-Associated Genes
Next, we investigated whether there is a known relationship between the candidate genes,
whose products may predispose individuals to severe COVID-19 disease, and SARS-CoV-2 infection.
For this, we used a proteomics and translatome dataset derived from SARS-CoV-2-infected and non-infected
cells [10] (Table S4) and 332 high confidence human SARS-CoV-2 interactor proteins, which had been
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identified by expressing 29 tagged SARS-CoV-2 proteins in HEK293T cells, followed by affinity purification
and mass spectrometric identification of binding partners [11] (Table S4). However, none of our six candidates
were shown to be regulated by or interact with SARS-CoV-2 (Tables S4 and S5).Diagnostics 2020, 10, x FOR PEER REVIEW 4 of 9 
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Figure 1. Gene products anticipated to be of potential relevance for COVID-19-related coagulopathy,
based on genes with a role in coagulation that are differentially expressed between females and males
(Table S1) and wh se expression correlates with age (Table S2). Candidate gene products were either
(A) procoagulants (ADAMTS13, F11, HGFAC, KLKB1), which display higher expression in males than
in females and increase with age, or (B) anticoagulants (C1QTNF1, SERPINA5), which display higher
expression in females than in males and decrease with age. A complete list of the relevant genes
overlapping between Table S1 and Table S2 is presented in Table S3. p-values were determined by
two-sided Student’s t-test. * p-value < 0.05.
3.3. Transferrin May Be Involved in COVID-19-Related Coagulopathy
While searching manually for additional candidates potentially involved in COVID-19-related
coagulopathy, we found transferrin to be upregulated in SARS-CoV-2-infected cells relative to
non-infected cells [10] (Figure 2A). Transferrin is a glycoprotein circulating in the blood that
is best known for its function as an iron carrier. It binds to cellular transferrin receptors and
delivers iron by receptor-mediated endocytosis [14,15]. However, transferrin has also been
shown to increase coagulation independent of its role as an iron transporter by interfering with
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antithrombin/SERPINC1-mediated inhibition of coagulation proteases including thrombin and factor
XIIa [16]. Hence, there might be a link between transferrin levels and coagulation in COVID-19 patients.Diagnostics 2020, 10, x FOR PEER REVIEW 6 of 9 
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Figure 2. SARS-CoV-2-induced (derived from [9]) transferrin (TF) expression and age- and
gender-specific expression of the procoagulant TF and its antagonist SERPINC1/antithrombin based on
GTEx data. Data are presented as violin blots to indicate the distribution of individual values and as
bar charts to facilitate comparisons. TF display d highe levels in SARS-CoV-2-inf cted cells than in
non-infected cells. Moreover, TF expression and the expression ration of TF and SERPINC1 increased
with age and were higher in females than in males. (A) TF protein abundance in uninfected (control)
and SARS-CoV-2-infected (virus) Caco-2 cells. p-values are the result of a two-sided Student’s t-test.
(B) TF expression (TPM) in females and males across six age groups. p-values were calculated using the
Wilcoxon rank sum test for independent groups. (C) SERPINC1 expression (TPM) in females and males
across six age groups. p-values were calculated using the Wilcoxon rank sum test for independent
groups. (D) Ratio of TF/SERPINC1 expression (TPM) in females and males across six age groups.
p-values were calculated using the Wilcoxon rank sum test for independent groups. * p-value < 0.05.
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GTEx data indicated that transferrin expression increased with age and was higher in males than
in females (Figure 2B). In contrast, expression of its antagonist antithrombin did not increase with age
and was similar in females and males (Figure 2C). Thus, the transferrin/antithrombin ratio increases
with age and is higher in males than in females (Figure 2D). This correlates with the risk of severe
and fatal COVID-19 disease, which is higher in males than in females and also increases with age [7].
Hence, an increased transferrin/antithrombin ratio may contribute to COVID-19-related coagulopathy
and more severe disease in older patients, in particular in males.
Transferrin was not included in the list of SARS-CoV-2-interacting proteins [11] (Table S4).
This suggests that transferrin is regulated in response to SARS-CoV-2 infection but does not directly
interact with SARS-CoV-2 proteins.
4. Discussion
Severe COVID-19 disease is associated with intravascular coagulation and thrombosis
(COVID-19-related coagulopathy) [1,4–6,17] and the risk of severe disease increases with age and is
higher in males than in females [7]. To identify factors involved in coagulation that may contribute
to COVID-19-related coagulopathy, we used genes associated with the GO term “blood coagulation”
and the GTEx database resulting in four procoagulants, whose expression was higher in males than
in females and increased with age (ADAMTS13, F11, HGFAC, KLKB1), and two anticoagulants,
whose expression was higher in females and decreased with age (C1QTNF1, SERPINA5).
However, these candidate factors were not found to be regulated in SARS-CoV-2-infected cells [10]
or among proteins known to interact with SARS-CoV-2 proteins [11]. Hence, they may rather
generally predispose individuals to coagulopathy, which is known to be higher in males and to
increase with age [8,9], than being directly involved in the disease processes mediated by SARS-CoV-2
infection. Therefore, these factors may also be relevant in age- and gender-related thrombosis formation
beyond COVID-19.
Our manual further investigations identified transferrin as a candidate factor, which may be
involved in COVID-19-related coagulopathy. The expression of transferrin, a known procoagulant [16],
was upregulated in SARS-CoV-2-infected cells, increased with age, and was higher in males than in
females. Moreover, a rise of transferrin levels was observed in patients during COVID-19 disease
progression [18]. Transferrin is an iron carrier protein that circulates and delivers iron to cells via
transferrin receptor binding followed by receptor-mediated endocytosis [14,15]. However, it also
promotes coagulation by iron-independent mechanisms as an inhibitor of antithrombin, which interferes
with the prothrombotic activity of coagulation proteases such as thrombin and factor XIIa [16].
Transferrin is primarily produced in the liver. However, (SARS-CoV-2-induced) locally produced
transferrin may contribute to COVID-19 pathology, even independent of circulating transferrin
levels [14,15,19–24]. For example, transferrin is produced in the brain [22], and high transferrin
levels have been associated with hypercoagulability and ischemic stroke [22]. Stroke is a significant
complication in COVID-19 [25] and is much more common in COVID-19 than, for example, in influenza
patients [26]. Both ischemic and hemorrhagic strokes are observed in COVID-19 patients [25]. Notably,
transferrin may not only contribute to ischemic strokes via inducing coagulation [27], it may also
increase the brain injury associated with hemorrhagic strokes by facilitating cellular iron uptake [28].
High transferrin levels have also been associated with diabetes and metabolic syndrome [23,29–31],
which are known risk factors for severe COVID-19 disease [32–34].
5. Conclusions
In conclusion, the role of transferrin in the course of COVID-19 disease and in particular
of COVID-19-related coagulopathy should be considered and further examined in ongoing
clinico-pathological investigations. If the role of transferrin is confirmed in the pathogenesis of severe
COVID-19 disease and in COVID-19-related coagulopathy, it is a candidate diagnostic marker for the
monitoring of COVID-19 progression and may guide the use of anticoagulants in COVID-19 patients.
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